IOSR Journal of Research & Method in Education (IOSR-JRME)
e-ISSN: 2320–7388, p- ISSN: 2320-737x Volume 15, Issue 3 Ser. 3 (May. – June. 2025), 56-70
www.iosrjournals.org

"Blood Brain Barrier Integrity And Neuroinflammatory Dysfunction"

Hariom Rajput, Anamika Sudhir Patne
Malhotra College Of Pharmacy, Bhopal, Madhya Pradesh,
Channabasweshwar Pharmacy College (Degree), Latur Maharashtra

Abstract:
The blood-brain barrier (BBB) plays a critical role in maintaining the central nervous system (CNS) by preserving the brain's internal environment. It regulates the exchange of substances and the movement of immune cells between the bloodstream and brain tissue. The BBB is mainly formed by microvascular endothelial cells that exhibit unique structural and functional characteristics. These properties are sustained through a coordinated interaction with various environmental signals, both hemodynamic and cellular. Together with astrocytes, pericytes, and neurons, these endothelial cells make up the neurovascular unit (NVU), a complex cellular network. The BBB employs tightly regulated transport systems to allow essential nutrients and metabolites into the brain, while simultaneously preventing harmful substances from entering through mechanisms like efflux transport and metabolic processing. Disruption of this barrier has been linked to several neurological diseases. However, whether BBB dysfunction causes these conditions or is a consequence of them remains unclear. Regardless, strategies aimed at repairing the BBB offer promising therapeutic potential for CNS disorders. This review outlines the core structure and functionality of the BBB under both normal and pathological conditions and explores emerging therapeutic approaches that target BBB restoration alongside disease management.

Keywords: *Blood-brain barrier, neurovascular unit, endothelial cells, tight junctions, CNS disorders, stroke, therapeutic strategies.*

Date of Submission: 28-05-2025 Date of Acceptance: 08-06-2025

I. Introduction:

Biological barriers are essential in preserving the structure and function of vertebrate organs. These barriers, composed of intercellular protein complexes within the plasma membrane, create paracellular diffusion limits that effectively separate internal body fluids from external environments—an indispensable process for the development and functionality of organ systems. Various organs, including the skin, intestines, kidneys, lungs, reproductive system, liver, oral mucosa, and central nervous system (CNS), possess distinct biological barriers tailored to their needs.[12] The CNS is uniquely shielded by three critical barriers: the blood-brain barrier (BBB), the blood–cerebrospinal fluid (CSF) barrier (BCB), and the arachnoid barrier. The BBB is formed by endothelial cells of cerebral microvessels, separating blood from the brain's interstitial fluid. Meanwhile, the BCB, located at the choroid plexus, consists of epithelial cells that separate the blood from the ventricular CSF. The arachnoid barrier lies between the blood and the CSF in the subarachnoid space. Collectively, these barriers regulate and restrict molecular traffic between the bloodstream and neural tissue or fluid compartments. Of the three, the BBB is the most stringent, exerting tight control over the brain's internal environment.[1] The BBB operates on three major levels. First, it serves as a physical barrier that prevents polar molecules such as ions from crossing between adjacent endothelial cells. This is achieved through tight junctions composed of proteins that connect corresponding proteins on neighboring cells. Second, the BBB functions as a chemical barrier via a variety of efflux transporters such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance-associated proteins (MRPs), which actively expel lipophilic and potentially harmful substances. Third, it acts as a metabolic barrier, with numerous enzymes that enable the brain to metabolize neurotransmitters and detoxify harmful compounds. These enzymes include cholinesterases, GABA transaminase, aminopeptidases, and various endopeptidases, as well as enzymes that process drugs and toxins. Through these mechanisms, the enzymatic barrier shields the brain from circulating neurotransmitters and xenobiotic substances.[12] Given its critical role in CNS homeostasis, any disruption to the BBB is often associated with the onset or progression of neurological and spinal pathologies. Indeed, compromised BBB function has been linked to a variety of severe brain conditions (see Figure 1). Due to this strong correlation, therapeutic strategies aimed at repairing or reinforcing the BBB are being explored as promising options for mitigating disease progression and improving patient outcomes. This review focuses on BBB dysfunctions observed in pathological states and discusses emerging therapeutic targets that aim to restore its function.[3]



Figure 1: BBB Function Has Been Linked To A Variety Of Severe Brain Conditions

II. The Function Of The Blood-Brain Barrier (BBB):

The blood-brain barrier (BBB) is essential for maintaining a controlled and stable microenvironment, which is critical for proper neuronal function and for safeguarding the central nervous system (CNS). One of its primary roles is to regulate ionic concentrations, vital for synaptic transmission and overall neural communication. The BBB and the blood–cerebrospinal fluid barrier (BCSFB) manage levels of key ions such as potassium (K^+), magnesium (Mg^{2+}), and calcium (Ca^{2+}). For example, potassium concentration in human plasma typically measures around 4.5 mM, whereas in cerebrospinal fluid (CSF) and interstitial fluid (ISF) it remains between 2.5 and 2.9 mM. Notably, this concentration remains consistent and is not influenced by external conditions such as physical activity, dietary intake, or disease states.[24] In addition to ionic regulation, the BBB plays a crucial role in nutrient transport to the brain. Due to its low permeability to water-soluble compounds, the BBB limits passive diffusion of essential nutrients. Instead, it utilizes highly selective transport systems to facilitate the uptake of critical molecules like glucose and amino acids, which cannot cross the barrier unaided. These transporters, expressed on both the luminal and abluminal surfaces of endothelial cells, contribute to the polarization of the BBB endothelium and are often region-specific.[14]\ Another vital function of the BBB is the regulation of neurotransmitter levels within the CNS. It ensures the separation of neurotransmitters between the central and peripheral systems, preventing dysregulation. During pathological conditions such as ischemic stroke, excess release of neurotransmitters like glutamate into the CSF may occur. This uncontrolled glutamate accumulation can lead to excitotoxicity and irreversible neuronal damage.[6] The BBB also restricts the entry of macromolecules from the bloodstream into the brain. Protein concentrations in the CSF are significantly lower than in plasma, as large plasma proteins are normally excluded from the CNS. Proteins such as albumin, prothrombin, and plasminogen, if allowed to cross into the brain, can initiate apoptotic pathways, resulting in nerve cell injury. For instance, prothrombin is converted to thrombin by factor Xa, and plasminogen is activated to plasmin by tissue plasminogen activator—both of which are naturally present in the brain. When the BBB is compromised, these large proteins can enter the brain and trigger a range of pathological events including seizures, gliosis, cellular proliferation, and neuronal death.[1] Moreover, the BBB acts as a defense mechanism by shielding

the brain from potentially harmful substances circulating in the blood. These may include endogenous metabolites, misfolded proteins, and exogenous toxins acquired from food, pharmaceuticals, or environmental contaminants. If such toxic compounds breach the BBB, they may disrupt neuronal signaling or directly induce neurodegeneration.[2]

III. Structure Of The Blood-Brain Barrier:

The formation of the blood-brain barrier (BBB) initiates during fetal development and is largely complete by birth, especially concerning the regulation of proteins and larger molecules. Structurally, the BBB is composed of brain microvascular endothelial cells (ECs) that line the inner walls of cerebral capillaries. These endothelial cells are intimately associated with pericytes embedded within the basement membrane and are ensheathed by the end-foot processes of astrocytes, which play a crucial role in maintaining endothelial cell function and BBB integrity.[18] One of the defining features of these endothelial cells is the presence of tight junctions (TJs), which contribute to the BBB's high selectivity. These cells lack fenestrations, exhibit minimal pinocytosis, and display polarized distribution of transport proteins, all of which support their barrier function. Key TJ proteins include occludin (OCLN), claudin-5 (CLN-5), and junctional adhesion molecules (JAMs), which collectively form a paracellular barrier that restricts the passage of most hydrophilic molecules and potentially harmful substances from the bloodstream into the brain.[19] Tight junction proteins are anchored to the actin cytoskeleton by cytoplasmic scaffolding components such as zona occludens proteins (ZO-1, ZO-2, ZO-3) and cingulin, which also contribute to signaling and proper membrane localization. Besides tight junctions, adherens junctions (AJs) also support the structural integrity of the BBB. A critical component of AJs is VE-cadherin (also known as Cadherin-5 or CD144), which governs cell adhesion, cytoskeletal organization, intracellular communication, BBB permeability through CLN-5 regulation, and even blood vessel formation. Disruption of these AJs can compromise BBB stability, leading to increased permeability.[26] However, the barrier's functional properties rely not only on the presence of TJ proteins like claudins and occludin but also on how these proteins are organized and interact across adjacent endothelial cells, highlighting the complexity of BBB regulation.

IV. Endothelial Cells (ECS):

The endothelial cells forming the brain's microvasculature are specialized and structurally distinct from those in other tissues. This specialization allows them to tightly regulate the exchange of ions, molecules, and immune cells between the bloodstream and the brain. In the central nervous system (CNS), these endothelial cells are sealed by tight junctions (TJs), which significantly limit the movement of polar solutes through the paracellular route. Compared to the endothelial cells of peripheral blood vessels, those at the BBB demonstrate extremely low levels of vesicular transport and transcytosis.[37] These cells also display membrane polarity—different types and levels of transporters are located on the luminal versus the basolateral side—enabling efficient control of substances entering and exiting the brain. Transcytosis, a vesicle-mediated transport mechanism from the apical to the basolateral side, facilitates the entry of large molecules like fatty acids and transferrin. While transcytosis is more active during early brain development, it becomes largely suppressed as the BBB matures. A resurgence in transcytosis activity is seen as an early sign of BBB disruption.[34] Efflux transporters located mainly on the luminal surface of endothelial cells include proteins like P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and various multidrug resistance-associated proteins (MRPs). These utilize ATP hydrolysis to expel potentially harmful compounds from the brain back into the bloodstream. Enzymes such as cytochrome P450s, monoamine oxidase (MAO), cholinesterases, and catechol-O-methyltransferase (COMT) further aid in detoxification. Conversely, members of the solute carrier (SLC) family, which operate without ATP, handle the bidirectional movement of smaller molecules and assist in clearing waste from the CNS.[30] Brain endothelial cells also have a higher density of mitochondria compared to those in peripheral tissues, enabling them to meet the energy demands of their complex transport functions. These cells express low levels of leukocyte adhesion molecules (e.g., E- and P-selectins), thereby limiting immune cell access to the brain—a key feature of its immune privilege. However, in neuroinflammatory conditions such as multiple sclerosis and stroke, elevated expression of these molecules allows immune cell infiltration.[7]

The Basement Membrane:

Surrounding the endothelial layer of blood vessels in the brain are two distinct basement membranes (BMs): the inner vascular BM and the outer parenchymal BM. The vascular BM is produced by endothelial cells and pericytes, while the parenchymal BM originates from astrocytic endfeet. Both membranes are rich in structural and signaling molecules, including laminins, type IV collagen, agrin, nidogen, and heparan sulfate proteoglycans.[1] These BMs are not identical—different isoforms of laminin distinguish them. Laminin α4 and α5 are typical of the vascular BM, while laminin α1 and α2 characterize the parenchymal BM. These structures act as physical and biochemical barriers and are critical to regulating cell behavior and maintaining BBB stability.

Enzymes like matrix metalloproteinases (MMPs) can degrade these membranes, contributing to BBB breakdown in neurological diseases.[14]

Astrocytes:

Astrocytes are the most prevalent glial cells in the CNS, supporting various essential functions such as ion homeostasis, pH regulation, neurotransmitter recycling, and compartmentalization of the neural environment. Their prevalence increases with brain complexity. Astrocytes also play a vital role in regulating cerebral blood flow by releasing vasoactive substances that adjust vascular tone.[19] At the microvascular level, astrocytes aid in the maturation and functionality of the BBB. They influence the expression of tight junctions and other markers in endothelial cells. In vitro studies have shown that when co-cultured with astrocytes, endothelial cells upregulate functional BBB markers like P-gp and transferrin receptors.[17] Astrocytic endfeet, which envelop brain capillaries, are instrumental in BBB maintenance. These endfeet contain critical proteins such as aquaporin-4 (Aqp4), dystrophin, and dystroglycan, which are linked to the basement membrane and help regulate water balance, ion transport, and neurotransmitter clearance. On the flip side, astrocytes can adopt reactive phenotypes under stress, releasing pro-inflammatory cytokines that may contribute to neuronal injury.[15] Although the initial development of the BBB occurs prior to full astrocyte interaction with the vasculature, astrocytes are indispensable for preserving BBB function postnatally

Mural Cells And Pericytes:

Mural cells encompass both vascular smooth muscle cells and pericytes. Pericytes are embedded in the abluminal side of brain microvessels and share the basement membrane with endothelial cells. They connect directly to endothelial cells through N-cadherin and gap junctions composed of connexins.[4] The brain contains a uniquely high density of pericytes, with a close 1:1 to 3:1 ratio to endothelial cells—far greater than the approximate 100:1 ratio seen in peripheral muscles. Pericytes are vital for BBB development (a process known as barriergenesis), vascular stability, and the regulation of cerebral blood flow and capillary diameter. They also manage extracellular matrix production, immune cell trafficking, and metabolic waste removal.[14] Pericytes express various receptors for regulatory molecules such as angiotensin I, catecholamines, endothelin-1, and vasopressin, indicating a role in cerebral autoregulation. While several markers—PDGFR-β, NG2, CD13, desmin, and others—are used to identify pericytes, none are entirely specific, making it difficult to fully define their roles in the BBB.[17]

Immune Cells:

CNS vasculature interacts with immune cells located both within the CNS and in peripheral circulation. The principal resident immune cells are perivascular macrophages and microglia. Perivascular macrophages, derived from blood monocytes, are located on the outer surface of the blood vessels and serve as phagocytic sentinels.[16] Microglial cells originate from yolk sac progenitors and populate the brain early in development. These cells are involved in shaping neural circuits, innate immunity, and tissue repair. They can also function as antigen-presenting cells in the context of adaptive immunity.[14] While the CNS limits immune cell entry under normal conditions, activated immune cells—such as T cells, neutrophils, and macrophages—can compromise the BBB during disease or injury by releasing reactive oxygen species, which increase vascular permeability. Understanding the interplay between immune cells and the BBB is crucial for elucidating the mechanisms of barrier disruption in various neurological disorders.

V. The Adrenergic System And Blood–Brain Barrier (BBB) Regulation:

Research dating back to the 1990s has underscored the role of the adrenergic system in modulating BBB permeability. Notably, activation of α-adrenoceptors—achieved either through intracerebroventricular injection of agonists or by electrically stimulating the locus coeruleus—was found to increase BBB permeability. Conversely, stimulating β-adrenoceptors or blocking α-adrenoceptors led to a reduction in BBB permeability. Interestingly, the inhibition of β-adrenoceptors had the opposite effect, promoting increased permeability. These physiological changes correlated with elevated pinocytotic activity in brain endothelial cells, although the structural integrity of tight junctions appeared unaffected. This indicates that adrenergic modulation of BBB function occurs primarily through vesicular transport pathways rather than junctional disruption.[37]

VI. Blood–Brain Barrier Dysfunction In Neurological Disorders:

Disruptions to the BBB often arise due to alterations in its cellular and structural components. These disturbances may involve changes in tight junction protein expression or localization, modifications in enzymatic activity, transporter regulation, and degradation of the basement membrane. Such dysfunctions allow serum proteins and immune cells to penetrate the brain parenchyma, compromising central nervous system (CNS) homeostasis and inflicting neuronal damage.[40] A growing body of evidence links BBB disruption to the onset

and progression of a variety of neurological and cerebrovascular diseases, including stroke, traumatic brain injury (TBI), multiple sclerosis (MS), brain tumors, Alzheimer's disease, Parkinson's disease, epilepsy, amyotrophic lateral sclerosis (ALS), cerebral edema, and glaucoma. While it remains uncertain whether BBB breakdown is a primary cause or a consequence of these conditions, it is clear that its compromise often worsens disease outcomes. For example, in disorders like epilepsy, the causal relationship between BBB impairment and pathology remains under investigation. Nonetheless, the presence of a disrupted BBB is a common pathological feature in many CNS disorders and is known to aggravate disease progression.[19]

Table 1: Pathophysiological Mechanisms of Blood–Brain Barrier Disruption, Associated Neurological Disorders, and Potential Therapeutic Targets:

S.NO	Pathophysiology of BBB Disruption	Associated Diseases	Therapeutic Targets
1	Upregulation of VEGF and Activation of VEGFR2	ALS, AD, PD, Epilepsy, Ischemic Stroke	Anti-VEGF antibody and VEGFR2 inhibitor (e.g., SU5416)
2	eNOS activation	Stroke, TBI	Selective eNOS inhibitor (e.g., cavtratin)
3	Upregulation of MMPs	Schizophrenia, Stroke, TBI	Inhibition of MMPs (e.g., GM6001)
4	Activation of endothelin receptors (ETA, ETB)	Stroke, Epilepsy	Inhibition of ETA and ETB (e.g., S-0139, BQ788)
5	Downregulation of VE-Cadherin	MS, Stroke	miR-27a/VE inhibition via CD5-2; ICAM antibody (Enlimomab)
6	Disorganization of adherens junctions	MS, Stroke	Stabilization with sphingosine-1-phosphate (S1P)
7	Reduced expression of tight junction (TJ) proteins	Depression, Stroke, Stress	Induction of TJ protein expression (e.g., miR-501-3p ASO, HDAC1 inhibitor MS-275)
8	Imbalance in AMP-activated protein kinase (AMPK) pathway	Stroke	AMPK activation using melatonin
9	Activation/upregulation of inflammatory cytokines (TNF-β, IL-1β, etc.)	Stroke, TBI, Cognitive Impairment, Seizures, MS	Cytokine inhibition (e.g., etanercept, anti-IL-6 antibody, natalizumab)
10	Oxidative stress via NOX4 and NOX5 activation	Stroke	NOX4/NOX5 inhibition (e.g., GKT136901, ML090)
11	Actin–myosin cytoskeletal contraction via myosin light chain phosphorylation	Stroke	RhoA/ROCK inhibition (e.g., fasudil)
12	Upregulation of MMPs	Stroke, TBI, Schizophrenia	MMP2/9 inhibition (e.g., SB-3CT)

Stroke:

Stroke is a major cause of long-term disability and is often accompanied by comorbid conditions such as hypertension and elevated blood sugar levels. Approximately 86% of stroke cases are ischemic, resulting from the blockage of blood and oxygen supply to specific areas of the brain. This leads to a cascade of complex pathophysiological processes, including damage to the blood-brain barrier (BBB). The disruption of the BBB typically begins immediately after the blood vessel becomes occluded and may persist for an extended period following the stroke. However, it remains unclear whether BBB damage is a cause or an effect of the injury that follows a stroke.[19] Research indicates that hypoxic and ischemic conditions can impair the BBB by breaking down tight junctions (TJs) and damaging endothelial cells, which increases barrier permeability. Under normal conditions, TJs maintain low permeability between cells, preventing unwanted passage of ions and molecules through the BBB. In ischemic stroke, TJ degradation occurs in a sequential and time-dependent manner, involving several cellular signaling pathways. Normally, TJs are stabilized by their connection to adherens junctions (AJs) like cadherins, which are anchored to the actin cytoskeleton by proteins such as ZO-1, ZO-2, and ZO-3. The actin-myosin cytoskeleton is composed of short filaments and monomers distributed between endothelial cells. During hypoxic stress, these actin filaments reorganize into linear stress fibers, and myosin light chain phosphorylation induces contraction of the cytoskeleton, increasing tension. This process weakens junctional seals, ultimately raising BBB permeability. Reduced expression of TJ transmembrane proteins—including occludin, claudins, zona occludens proteins, and junction adhesion molecules—has also been documented in brains affected by stroke.[37] Pericytes, an essential element of the neurovascular unit (NVU), closely interact with endothelial cells of capillaries and venules through physical contact and paracrine signaling. These cells play a vital role in maintaining BBB integrity due to their contractile and regulatory functions. In ischemic stroke, pericytes detach from their normal microvascular positions, leading to constricted blood vessels, reduced cerebral blood flow, and compromised BBB function. Studies in mouse stroke models have shown that vascular endothelial growth factor (VEGF) produced by pericytes contributes to BBB breakdown while also promoting angiogenesis after stroke.

VEGF is a key pro-angiogenic factor that stimulates endothelial cell proliferation and migration and can have beneficial effects if administered before or after stroke. However, VEGF treatment during the acute post-stroke phase can increase BBB leakage and cause cerebral hemorrhage, which enlarges the infarct area.[39] Astrocytes, another important NVU component, also influence BBB integrity in ischemic stroke. They have a dual role depending on the ischemic phase. During the acute phase, activated astrocytes release pro-inflammatory cytokines that inhibit axonal regeneration and contribute to tissue damage. Conversely, in the chronic phase, astrocytes support recovery by promoting neurite outgrowth, synapse formation, neurotrophic factor secretion, and BBB repair.[33] These effects are partly mediated by the release of soluble factors such as cytokines, VEGF, and nitric oxide (NO). Increased levels of pro-inflammatory cytokines, including interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α), have been found in animal models of both focal and global ischemia, as well as in cerebrospinal fluid from stroke patients. In vitro studies have demonstrated that ischemic conditions stimulate astrocytes and endothelial cells to secrete IL-8 and monocyte chemoattractant protein-1 (MCP-1). Another investigation revealed that human astrocytes under hypoxia induce inflammatory gene expression in cerebrovascular endothelial cells, increasing IL-8, ICAM-1, E-selectin, IL-1β, TNF-α, and MCP-1. Elevated cytokine levels enhance the expression of adhesion molecules on endothelial cells and neutrophils, facilitating leukocyte migration across the BBB. This recruitment process is accompanied by reduced tight junction proteins, altered adherens junction proteins like vinculin, and increased phosphotyrosine signaling, all indicating BBB disruption.[32] Furthermore, research by Mark KS et al. showed that hypoxia increased sucrose permeability by over 2.5 times in primary bovine brain microvascular endothelial cells, along with increased actin expression and altered localization of occludin, ZO-1, and ZO-2 proteins. Overall, these findings suggest that hypoxia-ischemia triggers a series of events disrupting tight junctions and compromising BBB integrity through mechanisms involving VEGF, cytokines, and cytoskeletal changes.[11]

Multiple Sclerosisi (MS):

Multiple sclerosis is an autoimmune disorder characterized by the attack of reactive T cells on antigens presented by macrophages or microglia expressing HLA-DR2a and HLA-DR2b molecules. This immune response results in the destruction of the myelin sheath and damage to the underlying axons. Activated macrophages release nitric oxide (NO) and various cytokines, including interferon-gamma, tumor necrosis factor-alpha (TNF-α), and interleukin-3 (IL-3), which damage oligodendrocytes and disrupt both myelin formation and the expression of myelin-related genes. Additionally, increased levels of reactive oxygen species (ROS) have been found in MS lesions, contributing to neural damage and playing a key role in the disease's pathology.[14][16] Both radiographic imaging and histopathological studies indicate that disruption of the blood-brain barrier is one of the earliest and critical steps in MS. Magnetic resonance imaging often reveals gadolinium-enhancing lesions, which serve as markers of BBB breakdown and active inflammation in MS lesions, making them important diagnostic indicators.[9] Histopathological evidence further shows that demyelination begins around blood vessels in the brain tissue. Since BBB breakdown allows immune cells to infiltrate the perivascular space, it is believed that loss of BBB integrity is an initial event in lesion formation. Supporting this, fibrinogen—a marker indicating increased endothelial permeability—has been found deposited in these regions, accompanied by a high influx of T cells in areas of demyelination. Abnormalities in tight junction proteins, such as the reduction of claudin-3, have been documented in both relapsing-remitting and progressive forms of MS, suggesting the opening of paracellular pathways. Additionally, failure to upregulate aquaporin-4 (AQP4), retraction of astrocyte end-feet from the glia limitans, and degradation of basement membrane proteins like laminin have all been observed in MS, further compromising BBB stability.[10]

Amyotrophic Lateral Sclerosis (ALS):

Amyotrophic lateral sclerosis is a fatal neurodegenerative disorder marked by the progressive loss of both upper and lower motor neurons located in the spinal cord and brainstem. Studies have linked BBB disruption with motor neuron loss, neuroinflammation, and subsequent motor deficits in ALS. Oxidative stress plays a major role in the degeneration of motor neurons and astrocyte dysfunction. Reactive oxygen species generated due to excitotoxic activation can impair glutamate transport in surrounding astrocytes, increasing excitatory stress and thereby promoting ALS progression. Key proteins such as aquaporin-4 (AQP4) and inward-rectifying potassium channels (Kir) are critical for maintaining BBB function through astrocyte support. In ALS, astrocytes lose their ability to regulate the local environment properly, disrupting BBB homeostasis, which contributes to neuronal dysfunction and death. Multiple in vivo studies using the SOD1-G93A mouse model of ALS—a model expressing the human mutant SOD1 gene linked to familial ALS—have confirmed BBB breakdown. These animals develop paralysis in one or more limbs within weeks after birth, mimicking the human disease.[9] Postmortem examinations of ALS patients also reveal BBB abnormalities. For example, Miyazaki et al. found that activation of matrix metalloproteinase-9 (MMP-9) preceded motor neuron degeneration and was associated with BBB damage in both ALS patients and animal models. Moreover, a dissociation between endothelial cells marked by

PCAM-1 and astrocytic end-feet marked by GFAP was reported. Elevated homocysteine levels in cerebrospinal fluid have been correlated with BBB impairment in ALS patients. Another study reported that reduced astrocytic expression of sonic hedgehog protein led to IL-1β mediated BBB disruption. IL-1β also increased the expression of pro-inflammatory chemokines such as CCL2, CCL20, and CXCL2, facilitating immune cell infiltration and neuroinflammation. Additionally, mutations in genes like TARDBP (encoding TDP-43, a transcription regulator) and angiopoietin (ANG) have been implicated in BBB disruption and inflammation in ALS. Damage to endothelial cells or impaired repair of the endothelium has also been suggested as a contributing factor in the disease's onset.[11]

Traumatic Brain Injury (TBI):

Traumatic brain injury (TBI) results from an external mechanical force impacting the brain, which can occur directly or indirectly through events like motor vehicle accidents, falls, assaults, or sports injuries. In the United States alone, approximately 2.5 million people require emergency medical attention annually for TBI, with over 5 million living with long-term disabilities caused by these injuries. The pathophysiology of TBI is typically divided into two phases: the initial primary injury and the subsequent secondary injury. The primary injury consists of immediate physical damage such as shearing forces, hematomas, and contusions. Secondary injury encompasses a range of delayed responses including oxidative stress, inflammation, brain swelling (edema), excitotoxicity, changes in vascular permeability, calcium imbalance, and disruption of the blood-brain barrier (BBB). Among these, BBB disruption driven by inflammatory processes plays a crucial role in worsening brain damage and long-term neurological impairments after TBI.[25] BBB breakdown is a hallmark pathological feature closely associated with neuroinflammation, leading to brain edema and neuronal death. Following injury, astrocytes and microglia rapidly respond by increasing the release of various mediators, which can further compromise BBB function. Normally, tight junction proteins between endothelial cells maintain BBB integrity and restrict paracellular permeability. However, TBI-induced damage to endothelial cells, altered expression of tight junction proteins, and degradation of the basement membrane collectively weaken the BBB and increase its permeability. This disruption initiates the recruitment of leukocytes, migration of inflammatory cells, release of proinflammatory cytokines, and production of reactive oxygen species (ROS). If unchecked, ROS contribute to further BBB damage by promoting lipid peroxidation, protein damage, and DNA fragmentation. Furthermore, BBB impairment activates the coagulation cascade, leading to microvascular thrombosis and ischemic injury.[33] BBB alterations after TBI occur in two phases: an early phase within 4 to 6 hours post-injury and a delayed phase peaking around three days later, primarily affecting the cortex and hippocampus on the injured side. Habgood and colleagues demonstrated that the BBB allows passage of molecules of varying sizes soon after injury, but that this permeability can be temporarily restored within hours to days. However, other research suggests BBB recovery may take much longer, possibly years. Recent findings have elucidated several inflammatory pathways contributing to BBB disruption in mild TBI (concussion) and associated hypertension. Oxidative stress has been identified as a primary driver of BBB impairment in blast-induced TBI models, with matrix metalloproteinases (MMPs) further mediating damage via NADPH oxidase-related oxidative mechanisms. Factors such as vascular endothelial growth factor (VEGF), MMPs, nitric oxide (NO), glutamate, and endothelin-1 released by activated astrocytes promote BBB breakdown following TBI. Potential biomarkers linked to BBB disruption include the cerebrospinal fluid (CSF)/serum albumin ratio, tight junction proteins, S100β protein, and plasma-soluble prion protein (PrPc).[34] Chronic traumatic encephalopathy (CTE), a neurodegenerative condition associated with repetitive mild TBIs, especially among athletes and military personnel, has also been linked to BBB dysfunction. Loss or discontinuity of tight junction proteins such as claudin-5 (CLN-5) and zonula occludens-1 (ZO-1) is observed around regions with perivascular phosphorylated tau (p-Tau) deposits, indicating compromised BBB integrity. Similar BBB disruption alongside p-Tau accumulation has been found in professional boxers diagnosed with schizophrenia, with leakage of blood components such as fibrinogen and immunoglobulin G (IgG) into the brain tissue. Moreover, increased caspase-3 activity and tau cleavage suggest that apoptosis and neuroinflammation contribute to prolonged BBB impairment after chronic TBI.[6]

Alzheimer's Disease (AD):

Alzheimer's disease is a progressive neurodegenerative disorder primarily characterized by memory loss and cognitive decline. A key pathological hallmark of AD is the accumulation of amyloid-beta (Aβ) peptides in the brain, which form amyloid plaques. BBB dysfunction is closely associated with AD pathogenesis, as elevated Aβ deposition can impair barrier integrity. Conversely, BBB disruption can facilitate increased Aβ production by activating β-secretase and γ-secretase enzymes.[8] At the BBB, the receptor for advanced glycation end products (RAGE) facilitates the transport of circulating Aβ into the brain, while the low-density lipoprotein receptor-related protein 1 (LRP-1) mediates Aβ clearance from the brain into the circulation. Studies comparing the hippocampi of elderly controls and AD patients showed increased RAGE expression and decreased LRP-1 levels at the brain microvasculature in AD, whereas neuronal expression patterns were opposite. These findings suggest that altered

expression of these receptors at the BBB may contribute to early AD pathology, with a significant portion of brain Aβ likely derived from systemic circulation.[7] Structural and functional changes in BBB components such as pericytes, astrocytes, endothelial cells, basement membrane proteins (e.g., argin), and tight junction proteins have been linked to increased AD risk. AD is also associated with reduced expression of glucose transporter GLUT-1 and efflux transporter p-glycoprotein. Neuroinflammation and oxidative stress, both promoting BBB impairment, further exacerbate AD progression by creating a pathogenic feedback loop. More research is needed to clarify whether BBB dysfunction is a cause or consequence of AD and how it contributes to disease advancement. Readers interested in more comprehensive details are referred to recent reviews on the topic.[4]

Parkinson's Disease (PD):

Parkinson's disease is a neurodegenerative disorder primarily affecting movement, characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of Lewy bodies—abnormal protein aggregates within neurons. Although several gene mutations have been implicated in PD, the disease is believed to result from a combination of genetic and environmental factors. For instance, the compound 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) readily crosses the BBB and induces Parkinsonian symptoms in animal models. Additionally, reduced function of P-glycoprotein at the BBB has been reported in PD patients, suggesting that BBB dysfunction may contribute to disease onset. Systemic vascular inflammation is also observed in PD, potentially damaging the BBB, although conclusive evidence of increased BBB permeability in patients is still lacking.[12]

Huntington's Disease (HD):

Huntington's disease is an inherited, autosomal dominant neurodegenerative disorder caused by an abnormal expansion of CAG trinucleotide repeats in the HTT gene, which encodes the huntingtin protein. The normal huntingtin protein contains 6 to 35 glutamine residues, but in HD patients, the repeat number exceeds 36, resulting in a mutant form whose functions are not fully understood. Huntingtin is involved in processes such as axonal transport and the regulation of brain-derived neurotrophic factor (BDNF), which supports survival of striatal neurons. Although mutant huntingtin is expressed throughout the body, only select brain regions, such as the hypothalamus, show neurodegeneration. Early symptoms of HD include disturbances in metabolism, sleep, and emotional regulation, linked to hypothalamic dysfunction. Disease progression leads to neuronal loss accompanied by cognitive decline, personality changes, and involuntary movements.[14] BBB disruption has been observed in HD animal models and postmortem human brain tissue, although its exact role in disease pathogenesis remains unclear. A major challenge in HD research is the lack of adequate rodent models that faithfully replicate human disease progression and neurodegeneration.[5]

Brain Tumors (BT):

Brain tumors have been shown to disrupt the integrity and permeability of the blood-brain barrier (BBB), while simultaneously promoting the development of a blood-tumor barrier (BTB). This BTB exhibits significant heterogeneity and is characterized by uneven permeability and active efflux mechanisms for various molecules. Approximately 30% of brain tumors are metastatic, commonly originating from primary cancers such as lung, breast, and melanoma. Research has demonstrated that tight junctions (TJs) between endothelial cells are compromised in gliomas and metastatic adenocarcinomas in humans. Specifically, a reduced expression of TJ proteins such as claudin-5 (CLN-5), occludin (OCLN), and claudin-1 (CLN-1) has been documented in brain microvessels of patients with glioblastoma multiforme, while the scaffold protein ZO-1 remains unchanged. Although the mechanisms underlying TJ loss in brain tumor vasculature are not fully understood, vascular endothelial growth factor (VEGF) and tumor-derived cytokines are believed to play pivotal roles in increasing BBB permeability and promoting cerebral edema. Elevated levels of aquaporin-4 (AQP4) have also been linked to BBB opening in several brain tumor types, including astrocytomas and metastatic adenocarcinomas. Animal studies have shown that AQP4 knockout mice survive better under brain edema conditions compared to wild-type mice, and AQP4 upregulation has also been observed in brain injury and ischemia models. Despite the brain's strong resistance to cancer cell infiltration, disruption of the BBB likely facilitates metastatic tumor cell invasion into the brain parenchyma.[17] The structural integrity of the BBB and BTB varies depending on the type of metastatic lesion and tumor subtype. For example, fenestration of BBB endothelial cells differs among the molecular subtypes of medulloblastoma, influencing drug transcytosis across the BTB and affecting therapeutic outcomes. Similarly, BBB characteristics and function vary in brain metastases arising from different breast cancer subtypes, with HER2-positive metastases showing higher expression of GLUT1 and breast cancer resistance protein (BCRP) than other subtypes. Preclinical studies also highlight heterogeneous BTB permeability, with the tumor core showing greater leakiness compared to peritumoral and surrounding brain areas. For instance, in an intracranial GBM8401 glioma model, liposomal doxorubicin was more concentrated within the tumor relative to adjacent brain tissue.[3]

Sepsis-Associated Encephalopathy (SAE):

Sepsis-associated encephalopathy (SAE) is a diffuse brain dysfunction occurring secondary to systemic inflammation without direct CNS infection. It frequently affects patients with severe systemic infections (about 70% of cases) and critically ill individuals recovering in intensive care units. The pathophysiology of SAE is complex and not fully understood but likely involves endothelial dysfunction, reduced cerebral blood flow and oxygen extraction, inflammatory mediators in circulation, and cerebral edema. These events lead to activation of microglia and brain endothelial cells, downregulation of TJs, and increased leukocyte infiltration, which exacerbates neurovascular inflammation and BBB dysfunction, causing neuronal injury and worsening brain dysfunction in sepsis. Animal models assessing BBB breakdown in septic encephalopathy used various markers including colloidal iron oxide, radiolabeled amino acids, and albumin. Pathological features such as increased pinocytosis, endothelial cell detachment, neuronal shrinkage, and astrocyte end-foot swelling are characteristic of BBB disruption in these models. The adrenergic system plays a role in this process, with suppressed β2-adrenoreceptor and stimulated α1-adrenoreceptor activity triggering inflammatory cascades that compromise BBB integrity. Further mechanistic details on BBB impairment in sepsis are available elsewhere.[1]

Hepatic Encephalopathy (HE):

Hepatic encephalopathy (HE) is a multifaceted neuropsychiatric syndrome caused by acute or chronic liver failure, manifesting as drowsiness, confusion, asterixis, hypertonia, seizures, and coma. It results from the liver's inability to detoxify neurotoxins, especially ammonia, leading to neurological impairments.[15] While an intact BBB has been observed in some HE cases, positron emission tomography studies indicate increased BBB permeability to ammonia. Altered expression of genes related to endothelial nitric oxide synthase and tight junction proteins has been reported in rat models during coma and brain edema stages of HE. Elevated ammonia levels correlate with brain edema and morphological changes in astrocytes (Alzheimer type II) in the basal ganglia of HE patients, along with reduced expression of claudin-12 (CLN-12). McClung reported that ammonia exposure can enlarge the effective pore size of the BBB under certain conditions. These findings collectively suggest that BBB disruption contributes to HE pathogenesis.[12]

HIV Encephalitis:

HIV infection in the CNS is linked to activation of astrocytes and macrophages, which release cytokines, chemokines, reactive oxygen species, and neurotoxins that disrupt neuronal signaling and promote leukoencephalopathy. TNF-α and other mediators such as nitric oxide, arachidonic acid, platelet-activating factor, and quinolinic acid contribute to the pathology. TNF-α, primarily secreted by HIV-infected macrophages, affects oligodendrocytes. Although the mechanism of HIV entry into the CNS is unclear, once inside, the virus compromises BBB integrity, facilitating further viral infiltration. For example, serum proteins have been detected in brain tissue from patients with HIV-associated dementia. Postmortem studies also report reduced or fragmented TJ proteins like ZO-1 and occludin in brains of patients with HIV encephalitis. In gp120 transgenic mouse models, albumin leakage and increased expression of adhesion molecules ICAM-1 and VCAM-1 have been observed, indicating BBB disruption by circulating gp120. gp120 exerts cytotoxic effects on brain endothelial cells, possibly through upregulation of metalloproteinases and oxidative stress, impairing BBB viability.[6] Despite antiretroviral therapy, HIV-associated dementia (HAD) and cognitive decline persist in some patients. An imbalance between matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) has been implicated in BBB damage and HAD pathogenesis. HIV-infected cells also secrete viral proteins (gp120, Tat, Nef) and inflammatory mediators that reduce BBB integrity and function.[3]

Epilepsy

Numerous studies link BBB disruption with epilepsy, where BBB damage can both cause and result from seizure activity. Seizures have been shown to impair BBB function, and conversely, BBB breakdown may initiate or worsen epileptic conditions. Post-seizure BBB opening is often associated with acute hypertension. Disruption has also been observed following traumatic brain injury (TBI), status epilepticus (SE), and temporal lobe epilepsy (TLE), with BBB leakage occurring minutes after SE and lasting hours to days, indicating BBB disruption as a possible consequence of seizures.[1] Contrast-enhanced MRI studies have revealed BBB leakage in epilepsy patients, and brain tissue analyses show elevated albumin in the parenchyma, supporting blood-to-brain leakage. Reduced GLUT-1 expression and impaired glucose metabolism have also been observed in patient samples.[7] BBB disruption is especially prominent during the acute phase post-SE but extends into the latent phase without immediate seizure onset, suggesting a role in epileptogenesis rather than immediate seizure induction. After TBI, BBB disruption occurs early, but seizures emerge later. Osmotic shock-induced BBB opening can provoke seizures. Additionally, diseases that compromise BBB function, such as stroke, infection, inflammation, and TBI, are associated with epilepsy and seizures. GLUT-1 deficiency, impairing BBB transport, also causes epilepsy.[18] Chronic BBB disruption has been documented in epilepsy, with leakage gradually declining but persisting weeks

to months in certain brain regions. Resected brain tissue from drug-resistant epilepsy patients shows BBB breakdown through albumin staining, and BBB leakage correlates with seizure severity in epileptic rats during chronic phases. Opening the BBB with mannitol in chronic epilepsy models increased seizure frequency. These findings suggest that prolonged BBB disruption may lower seizure threshold and increase seizure frequency over time. Similar observations have been made in post-traumatic epilepsy, where sustained BBB permeability correlates with abnormal EEG and reduced cerebral blood flow. Epileptogenic brain areas with BBB leakage show more intense electrical spiking than less affected regions. Overall, these data support the idea that BBB impairment can drive epileptogenesis and worsen established epilepsy in the diseased brain.[9]

Schizophrenia:

Disruption of the blood-brain barrier (BBB) has been linked to psychiatric disorders, including schizophrenia. A modest association exists between schizophrenia and the tight junction protein claudin-5 (CLN-5). Notably, approximately 30% of individuals with schizophrenia carry the 22q11 deletion syndrome (22q11DS), which results in haploinsufficiency of CLN-5. Experimental studies using adeno-associated virus-mediated knockdown of CLN-5 have demonstrated BBB disruption accompanied by behavioral abnormalities. Moreover, both in vitro and in vivo experiments indicate that antipsychotic drugs induce a dose-dependent increase in CLN-5 expression. However, analysis of postmortem brain tissue from schizophrenia patients revealed irregular CLN-5 expression compared to age-matched controls.[14] Further research has linked the severity of schizophrenia, including overall symptom burden and negative symptom clusters, with compromised BBB function. In particular, deficit schizophrenia appears to stem from BBB dysfunction due to damage in paracellular and vascular routes.

Meningitis:

The integrity of the BBB can be compromised during meningitis, which may facilitate the entry of various substances into the brain and contribute to inflammation of the meninges. Recent findings demonstrate that meningitis-causing Escherichia coli can induce the expression of PDGF-B and ICAM-1 in both in vitro and in vivo models. Increased levels of these molecules may disrupt the BBB by downregulating tight junction proteins and promoting the recruitment of immune cells like neutrophils and monocytes. Additionally, microglial cells play a crucial role in neuroinflammation by releasing cytokines and chemokines, which promote leukocyte infiltration through the BBB, further damaging its integrity.

VII. Biological Targets For Restoring BBB Integrity:

The neurovascular unit (NVU) is composed of endothelial cells, astrocytes, and pericytes, with tight junction proteins such as CLN-5, occludin (OCLN), and zonula occludens-1 (ZO-1) located on endothelial cell membranes. These proteins tightly seal adjacent endothelial cells, regulating molecular exchange between the vascular and brain compartments. Various types of brain injuries activate molecular pathways that compromise BBB integrity. Key molecules involved in BBB disruption include vascular endothelial growth factors (VEGFs), matrix metalloproteinases (MMPs), and endothelins (ETs).[19] Interactions between microglia and astrocytes significantly influence BBB integrity and promote neuroinflammation. Microglia are particularly sensitive to brain injury or infection and rapidly activate into a pro-inflammatory M1 phenotype, releasing factors such as tumor necrosis factor (TNF), interleukin-1 beta (IL-1β), and reactive oxygen species (ROS). These mediators then stimulate astrocytes to adopt a reactive A1 phenotype. Activated A1 astrocytes secrete chemokines that perpetuate microglial activation, along with MMPs that degrade the extracellular matrix, and VEGF-A, which disrupts tight junction proteins CLN-5 and OCLN. This cascade leads to BBB breakdown and increased infiltration of immune cells (refer to Figure 3). Research suggests that targeting these molecules may help restore BBB integrity, as summarized in Table 1, with further discussion provided below.



Figure 2: Neurovascular Unit & BBB Section

VEGFs:

VEGFs (A, B, C, D) promote blood vessel growth and increase BBB permeability via VEGF receptors. Brain injury raises VEGF levels, which reduce tight junction proteins like claudin-5 and occludin, causing BBB disruption. Blocking VEGF or its receptors in animal models reduces BBB damage, inflammation, and brain swelling, highlighting VEGF inhibition as a therapeutic target.[31]

Matrix Metalloproteinases (MMPS):

MMPs are enzymes that degrade the extracellular matrix and tight junction proteins, increasing BBB permeability and enabling immune cell infiltration. Inhibiting MMPs, especially MMP-2 and MMP-9, protects BBB integrity and reduces brain edema in stroke and injury models. Some antibiotics like minocycline also inhibit MMPs, aiding BBB recovery.[9]

Endothelins:

Endothelins, especially ET-1, cause blood vessel constriction and contribute to BBB breakdown and brain swelling after strokes. Blocking endothelin receptors improves BBB integrity by reducing MMP activity and preserving tight junction proteins in animal models.[16]

Adherens Junctions:

Loss of adherens junction proteins like cadherins is linked to BBB breakdown in stroke and brain injury. Increasing cadherin levels, using agents like CD5-2 or sphingosine-1-phosphate, helps restore BBB integrity by stabilizing cell contacts.[18]

Tight Junctions:

Reduced expression of tight junction proteins (claudin-5, ZO-1, occludin) is common in neurological disorders. Treatments such as antidepressants, histone deacetylase inhibitors, melatonin, and antioxidants can restore these proteins and improve BBB function after injury or stress.[4]

Endothelium:

The BBB endothelium regulates blood flow and protects the brain. Damage leads to inflammation and oxidative stress. Therapies targeting endothelial oxidative damage, including antioxidant enzymes and antibodies against adhesion molecules, have shown promise in protecting and repairing the BBB.[14]

Cytokines:

Inflammatory cytokines (TNF-α, IL-1β, IL-6) increase BBB permeability. Blocking these cytokines or adhesion molecules with antibodies helps preserve BBB integrity and reduce inflammation in CNS diseases.[6]

Oxidative Stress:

Excess reactive oxygen species (ROS) damage BBB by activating enzymes like NOX4 and NOX5. Inhibitors of these enzymes and activators of antioxidant regulators like Nrf2 (e.g., metformin, sulforaphane) protect and restore BBB function after brain injury.[1]

Actin-Myosin Cytoskeleton:

Activation of the RhoA/ROCK pathway increases cytoskeletal tension, disrupts tight junctions, and widens gaps between endothelial cells, damaging the BBB. ROCK inhibitors such as fasudil and Y-27632 reduce BBB damage and improve outcomes in stroke and neuroinflammation models.[7]

VIII. Blood-Brain Barrier Market Overview:

In 2024, the global market addressing blood-brain barrier (BBB) challenges is valued at approximately USD 36 million. It is expected to witness significant growth, reaching nearly USD 2,904 million by 2035, expanding at a robust compound annual growth rate (CAGR) of 49% over the forecast period from 2024 to 2035. Innovations in BBB-targeting drugs and delivery systems are designed to bypass or traverse the barrier's selective permeability, enabling effective transport of therapeutic compounds directly into the brain. These advancements are paving the way for more efficient treatments for central nervous system (CNS) disorders.



FIGURE 3: ANNUAL GROWTH RATE (CAGR) OF 49% OVER THE FORECAST PERIOD FROM 2024 TO 2035

IX. Rising Demand And Innovation In Blood-Brain Barrier Therapeutics:

In recent years, there has been a surge in research initiatives and financial investments aimed at addressing the complexities faced by drug developers in targeting the blood-brain barrier (BBB). This growing interest is largely fueled by the increasing prevalence of neurological disorders such as Alzheimer's and Parkinson's disease. As a result, there is a rising demand for therapeutic approaches capable of effectively bypassing or penetrating the BBB, which is expected to stimulate innovation and drive significant market growth. Emerging advancements include specialized drug delivery systems, nanotechnology-based carriers, and medical devices specifically designed to enhance the delivery of therapeutic agents to the brain. These innovations aim to improve treatment outcomes for patients suffering from central nervous system (CNS) disorders by facilitating more efficient transport of drugs across the BBB. Data from the World Health Organization (WHO) highlights the urgent need for effective CNS treatments. Neurological disorders such as Alzheimer's disease, brain tumors, multiple sclerosis, Parkinson's disease, and stroke collectively represent the second leading cause of death and the primary cause of long-term disability worldwide. As of 2021, approximately 3.4 billion individuals globally were reported to suffer from various CNS-related conditions. In the United States alone, over 6 million individuals live with Alzheimer's disease—a number projected to nearly double to 13 million by 2050. Additionally, Parkinson's disease affects nearly one million Americans, with about 90,000 new cases diagnosed each year.



Figure 4: Growth In Licensing Activity; Approximately 20% Of The Licensing Agreements Were Signed Between Players Based In North America And Europe.

Over the years, sustained research and development efforts have led to the emergence of a wide range of innovative blood-brain barrier (BBB) technologies. These solutions are primarily aimed at either temporarily modifying the BBB's permeability or enhancing the ability of therapeutic agents to cross this natural barrier effectively. Such technological progress has not only expanded the capabilities of CNS drug delivery but has also attracted numerous new players to the field, indicating strong potential for continued market expansion in the near future. At present, the BBB market is significantly influenced by strategic technology licensing and partnership activities. Pharmaceutical companies are increasingly collaborating with platform technology providers to enhance their drug development pipelines, leveraging specialized BBB-targeting techniques to accelerate the delivery of effective treatments for neurological conditions.

X. Conclusion:

The blood-brain barrier (BBB) is a crucial biological barrier that preserves the brain's stable environment by regulating the movement of substances between the bloodstream and brain tissue. It protects the brain from harmful agents such as toxins, pathogens, and inflammation. Disruption of the BBB contributes to the development and progression of various neurological and cerebrovascular diseases, both acute and chronic. This review has outlined the BBB's functions, its role in neurological disorders, and potential therapeutic targets for restoring its integrity. Key molecular pathways involved in BBB disruption include VEGF, TNF-α, MMPs, and endothelins, with several small molecules showing promise as therapeutic targets. However, effective clinical treatments to fully restore BBB function are still lacking.[14] More rigorous preclinical and clinical research is necessary to confirm these mechanisms and carefully evaluate the benefits and risks of targeting these molecules for BBB repair. Understanding how BBB dysfunction relates to brain pathology is essential for developing targeted treatments. It remains unclear in many cases whether BBB breakdown causes neurological disease or results from it, but its presence clearly worsens outcomes. Therefore, therapies that simultaneously address both BBB repair and brain tissue damage are likely to be more effective than those focusing on either alone.Given the brain's complex regional diversity, future therapies should consider region-specific BBB changes. Emerging technologies such as transcriptomics, proteomics, and single-cell RNA sequencing offer powerful tools to explore BBB damage mechanisms in distinct brain areas, paving the way for more precise and effective interventions. The blood-brain barrier market is poised for remarkable growth, driven by rising neurological disease prevalence and the urgent need for effective CNS therapies. With a projected CAGR of 49% from 2024 to 2035, the market's expansion reflects growing interest in novel drug delivery technologies capable of overcoming the BBB's selective permeability. Continued advancements in targeted therapeutics, nanotechnology, and innovative delivery platforms are expected to revolutionize treatment approaches for CNS disorders, offering new hope for millions of patients worldwide. As research and collaborations accelerate, the BBB market is set to become a vital frontier in modern neuroscience and pharmaceutical development.

Abbreviations:

1	**Abbreviation**	**Full Form**
2	AD	Alzheimer's Disease
3	ALS	Amyotrophic Lateral Sclerosis
4	BBB	Blood-Brain Barrier
5	BMECs	Human Brain Microvascular Endothelial Cells
6	CLN-5	Claudin-5
7	CNS	Central Nervous System
8	GLUT-1	Glucose Transporter
9	HDAC	Histone Deacetylases
10	HDAC I	HDAC inhibitor
11	HIV	Human Immunodeficiency Virus
12	ICAM1	Intercellular Adhesion Molecule 1
13	MLC	Myosin Light Chain
14	MMPs	Matrix Metalloproteinases
15	MRP	Multidrug Resistance-Associated Protein
16	MS	Multiple Sclerosis
17	NOX	NADPH Oxidase
18	Nrf2	Nuclear Factor Erythroid 2 (NFE2)-Related Factor 2
19	NVU	Neurovascular Unit
20	OCLN	Occludin
21	PD	Parkinson's Disease
22	P-gp	P-glycoprotein
23	VEGF	Vascular Endothelial Growth Factor
24	ROCK	RhoA/Rho-Associated Protein Kinase
25	ROS	Reactive Oxygen Species
26	VCAM1	Vascular Cell Adhesion Protein 1
27	VEGFR2	Vascular Endothelial Growth Factor Receptor-2
28	TJs	Tight Junctions
29	ZO-1	Zona Occludens-1
30	3D	Three Dimensional

Acknowledgment:

The authors would like to express sincere gratitude to the faculty and staff of Malhotra College of Pharmacy, Bhopal, Madhya Pradesh, and Channabasweshwar Pharmacy College (Degree), Latur, Maharashtra, for their invaluable support and guidance throughout this research. Special thanks to peers and mentors whose encouragement and constructive feedback greatly contributed to the completion of this work.

Author Contributions:

Hariom Rajput* (Malhotra College of Pharmacy, Bhopal, Madhya Pradesh) conceptualized the study, conducted the primary research, data analysis, and manuscript drafting. He also served as the corresponding author and coordinated communication between the institutions involved.

Anamika Sudhir Patne (Assistant Professor, Channabasweshwar Pharmacy College (Degree), Latur, Maharashtra) provided critical academic, contributed to the literature review, and offered insightful revisions and suggestions that enhanced the overall quality of the manuscript.

Reference:

[1] Abbott N.J., Patabendige A.A.K., Dolman D.E.M., Yusof S.R., Begley D.J. Structure And Function Of The Blood–Brain Barrier. Neurobiol. Dis. 2010;37:13–25. Doi: 10.1016/J.Nbd.2009.07.030.

[2] Abbott N.J., Rönnbäck L., Hansson E. Astrocyte–Endothelial Interactions At The Blood–Brain Barrier. Nat. Rev. Neurosci. 2006;7:41–53. Doi: 10.1038/Nrn1824.

[3] Ballabh P., Braun A., Nedergaard M. The Blood–Brain Barrier: An Overview: Structure, Regulation, And Clinical Implications. Neurobiol. Dis. 2004;16:1–13. Doi: 10.1016/J.Nbd.2003.12.016.

[4] Ben-Zvi A., Lacoste B., Kur E., Andreone B.J., Mayshar Y., Yan H., Gu C. Mfsd2a Is Critical For The Formation And Function Of The Blood–Brain Barrier. Nature. 2014;509:507–511. Doi: 10.1038/Nature13324.

[5] Bhalerao A., Sivandzade F., Archie S.R., Chowdhury E.A., Noorani B., Cucullo L. In Vitro Modeling Of The Neurovascular Unit: Advances In The Field. Fluids Barriers CNS. 2020;17:22. Doi: 10.1186/S12987-020-00183-7.

[6] Bernacki J., Dobrowolska A., Nierwińska K., Małecki A. Physiology And Pharmacological Role Of The Blood-Brain Barrier. Pharmacol. Rep. PR. 2008;60:600–622.

[7] Betz A.L., Firth J.A., Goldstein G.W. Polarity Of The Blood-Brain Barrier: Distribution Of Enzymes Between The Luminal And Antiluminal Membranes Of Brain Capillary Endothelial Cells. Brain Res. 1980;192:17–28. Doi: 10.1016/0006-8993(80)91004-5.

[8] Betz A.L., Goldstein G.W. Polarity Of The Blood-Brain Barrier: Neutral Amino Acid Transport Into Isolated Brain Capillaries. Science. 1978;202:225–227. Doi: 10.1126/Science.211586.

[9] Bien-Ly N., Yu Y.J., Bumbaca D., Elstrott J., Boswell C.A., Zhang Y., Luk W., Lu Y., Dennis M.S., Weimer R.M. Transferrin Receptor (Tfr) Trafficking Determines Brain Uptake Of Tfr Antibody Affinity Variants. J. Exp. Med. 2014;211:233–244. Doi: 10.1084/Jem.20131660.

[10] Brightman M.W., Reese T.S. Junctions Between Intimately Apposed Cell Membranes In The Vertebrate Brain. J. Cell Biol. 1969;40:648–677. Doi: 10.1083/Jcb.40.3.648.

[11] Bradbury M.W., Stubbs J., Hughes I.E., Parker P. The Distribution Of Potassium, Sodium, Chloride And Urea Between Lumbar Cerebrospinal Fluid And Blood Serum In Human Subjects. Clin. Sci. 1963;25:97–105.

[12] Coomber B.L., Stewart P.A. Morphometric Analysis Of CNS Microvascular Endothelium. Microvasc. Res. 1985;30:99–115. Doi: 10.1016/0026-2862(85)90042-1.

[13] Daneman R., Prat A. The Blood-Brain Barrier. Cold Spring Harb. Perspect. Biol. 2015;7:A020412. Doi: 10.1101/Cshperspect.A020412.

[14] Farkas A., Fazakas C., Haskó J., Krizbai I., Molnár J., Nyúl-Tóth A., Wilhelm I. Molecular Structure And Function Of Biological Barriers. Acta Biol. Szeged. 2015;59:39–50.

[15] Gingrich M.B., Junge C.E., Lyuboslavsky P., Traynelis S.F. Potentiation Of NMDA Receptor Function By The Serine Protease Thrombin. J. Neurosci. 2000;20:4582. Doi: 10.1523/JNEUROSCI.20-12-04582.2000.

[16] Gingrich M.B., Traynelis S.F. Serine Proteases And Brain Damage—Is There A Link? Trends Neurosci. 2000;23:399–407. Doi: 10.1016/S0166-2236(00)01617-9.

[17] Hamm S., Dehouck B., Kraus J., Wolburg-Buchholz K., Wolburg H., Risau W., Cecchelli R., Engelhardt B., Dehouck M.P. Astrocyte Mediated Modulation Of Blood-Brain Barrier Permeability Does Not Correlate With A Loss Of Tight Junction Proteins From The Cellular Contacts. Cell Tissue Res. 2004;315:157–166. Doi: 10.1007/S00441-003-0825-Y.

[18] Hansen A.J. Effect Of Anoxia On Ion Distribution In The Brain. Physiol. Rev. 1985;65:101–148. Doi: 10.1152/Physrev.1985.65.1.101.

[19] Harris E.S., Nelson W.J. VE-Cadherin: At The Front, Center, And Sides Of Endothelial Cell Organization And Function. Curr. Opin. Cell Biol. 2010;22:651–658. Doi: 10.1016/J.Ceb.2010.07.006.

[20] Hoffmann A., Dege T., Kunze R., Ernst A.-S., Lorenz H., Böhler L.-I., Korff T., Marti H.H., Heiland S., Bendszus M. Early Blood–Brain Barrier Disruption In Ischemic Stroke Initiates Multifocally Around Capillaries/Venules. Stroke. 2018;49:1479–1487. Doi: 10.1161/STROKEAHA.118.020927.

[21] Jeong S.M., Hahm K.D., Shin J.W., Leem J.G., Lee C., Han S.M. Changes In Magnesium Concentration In The Serum And Cerebrospinal Fluid Of Neuropathic Rats. Acta Anaesthesiol. Scand. 2006;50:211–216. Doi: 10.1111/J.1399-6576.2006.00925.X.

[22] Kadry H., Noorani B., Cucullo L. A Blood–Brain Barrier Overview On Structure, Function, Impairment, And Biomarkers Of Integrity. Fluids Barriers CNS. 2020;17:69. Doi: 10.1186/S12987-020-00230-3.

[23] Keep R.F., Ennis S.R., Beer M.E., Betz A.L. Developmental Changes In Blood-Brain Barrier Potassium Permeability In The Rat: Relation To Brain Growth. J. Physiol. 1995;488:439–448. Doi: 10.1113/Jphysiol.1995.Sp020978.

[24] Knowland D., Arac A., Sekiguchi K.J., Hsu M., Lutz S.E., Perrino J., Steinberg G.K., Barres B.A., Nimmerjahn A., Agalliu D. Stepwise Recruitment Of Transcellular And Paracellular Pathways Underlies Blood-Brain Barrier Breakdown In Stroke. Neuron. 2014;82:603–617. Doi: 10.1016/J.Neuron.2014.03.003.

[25] Loscher W., Potschka H. Blood-Brain Barrier Active Efflux Transporters: ATP-Binding Cassette Gene Family. Neurorx. 2005;2:86–98. Doi: 10.1602/Neurorx.2.1.86.

[26] Moos T., Møllgård K. Cerebrovascular Permeability To Azo Dyes And Plasma Proteins In Rodents Of Different Ages. Neuropathol. Appl. Neurobiol. 1993;19:120–127. Doi: 10.1111/J.1365-2990.1993.Tb00416.X.

[27] Minn A., Ghersi-Egea J.F., Perrin R., Leininger B., Siest G. Drug Metabolizing Enzymes In The Brain And Cerebral Microvessels. Brain Res. Brain Res. Rev. 1991;16:65–82. Doi: 10.1016/0165-0173(91)90020-9.

[28] Nadal A., Fuentes E., Pastor J., Mcnaughton P.A. Plasma Albumin Is A Potent Trigger Of Calcium Signals And DNA Synthesis In Astrocytes. Proc. Natl. Acad. Sci. USA. 1995;92:1426–1430. Doi: 10.1073/Pnas.92.5.1426.

[29] Nischwitz V., Berthele A., Michalke B. Speciation Analysis Of Selected Metals And Determination Of Their Total Contents In Paired Serum And Cerebrospinal Fluid Samples: An Approach To Investigate The Permeability Of The Human Blood-Cerebrospinal Fluid-Barrier. Anal. Chim. Acta. 2008;627:258–269. Doi: 10.1016/J.Aca.2008.08.018.

[30] Olsson Y., Klatzo I., Sourander P., Steinwall O. Blood-Brain Barrier To Albumin In Embryonic New Born And Adult Rats. Acta Neuropathol. 1968;10:117–122. Doi: 10.1007/BF00691305.
[31] Preston J.E., Al-Sarraf H., Segal M.B. Permeability Of The Developing Blood-Brain Barrier To 14C-Mannitol Using The Rat In Situ Brain Perfusion Technique. Dev. Brain Res. 1995;87:69–76. Doi: 10.1016/0165-3806(95)00060-Q.
[32] Reese T.S., Karnovsky M.J. Fine Structural Localization Of A Blood-Brain Barrier To Exogenous Peroxidase. J. Cell Biol. 1967;34:207–217. Doi: 10.1083/Jcb.34.1.207.
[33] Saunders N.R. Development Of The Blood—Brain Barrier To Macromolecules. In: Segal M.B., Editor. Barriers And Fluids Of The Eye And Brain. Macmillan Education UK; London, UK: 1992. Pp. 128–155.
[34] Saunders N.R., Knott G.W., Dziegielewska K.M. Barriers In The Immature Brain. Cell. Mol. Neurobiol. 2000;20:29–40. Doi: 10.1023/A:1006991809927.
[35] Shen S., Zhang W. ABC Transporters And Drug Efflux At The Blood-Brain Barrier. Rev. Neurosci. 2010;21:29–53. Doi: 10.1515/REVNE.
[36] Taddei A., Giampietro C., Conti A., Orsenigo F., Breviario F., Pirazzoli V., Potente M., Daly C., Dimmeler S., Dejana E. Endothelial Adherens Junctions Control Tight Junctions By VE-Cadherin-Mediated Upregulation Of Claudin-5. Nat. Cell Biol. 2008;10:923–934. Doi: 10.1038/Ncb1752.
[37] Tauc M., Vignon X., Bouchaud C. Evidence For The Effectiveness Of The Blood—CSF Barrier In The Fetal Rat Choroid Plexus. A Freeze-Fracture And Peroxidase Diffusion Study. Tissue Cell. 1984;16:65–74. Doi: 10.1016/0040-8166(84)90019-3.
[38] Westergaard E., Brightman M.W. Transport Of Proteins Across Normal Cerebral Arterioles. J. Comp. Neurol. 1973;152:17–44. Doi: 10.1002/Cne.901520103.
[39] Wilhelm I., Fazakas C., Haskó J., Krizbai I. Molecular Structure And Function Of Biological Barriers. Acta Biol. Szeged. 2015;59:39–50.
[40] Wolburg H., Lippoldt A. Tight Junctions Of The Blood-Brain Barrier: Development, Composition And Regulation. Vasc. Pharm. 2002;38:323–337. Doi: 10.1016/S1537-1891(02)00200-8.